GRI Bio Inc. (GRI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, GRI Bio Inc. (GRI) has a cash flow conversion efficiency ratio of -0.349x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.69 Million) by net assets ($10.54 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see GRI market cap overview for the company's overall valuation and market capitalisation.
GRI Bio Inc. - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how GRI Bio Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
GRI Bio Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of GRI Bio Inc. ranked by their cash flow conversion efficiency. Explore GRI Bio Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Linkage Global Inc
NASDAQ:UZX
|
N/A |
|
Fintec Global Bhd
KLSE:0150
|
-0.007x |
|
iSpecimen Inc
NASDAQ:ISPC
|
-0.397x |
|
GuocoLand (Malaysia) Bhd
KLSE:1503
|
-0.003x |
|
Archon Minerals Ltd
V:ACS
|
-0.007x |
|
EMPYREAN ENERGY LS-002
F:E1E
|
N/A |
|
FW Thorpe PLC
LSE:TFW
|
0.081x |
|
REDSUN PROPERTIES GROUP
F:0RJ
|
N/A |
Annual Cash Flow Conversion Efficiency for GRI Bio Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of GRI Bio Inc. from 2018 to 2025. View GRI live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.01 Million | $-10.19 Million | -1.695x | +20.61% |
| 2024-12-31 | $4.03 Million | $-8.61 Million | -2.136x | +93.85% |
| 2023-12-31 | $259.00K | $-8.99 Million | -34.710x | -5298.57% |
| 2022-12-31 | $-1.62 Million | $-1.08 Million | 0.668x | +272.39% |
| 2021-12-31 | $-4.72 Million | $-847.00K | 0.179x | -92.97% |
| 2020-12-31 | $-1.45 Million | $-3.71 Million | 2.549x | +384.06% |
| 2019-12-31 | $3.21 Million | $-2.88 Million | -0.897x | +94.21% |
| 2018-12-31 | $152.94K | $-2.37 Million | -15.503x | -- |
About GRI Bio Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung … Read more